Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Sara Tolaney

Sara Tolaney

MD, MPH
Dana Farber Cancer Institute, Boston, MA
Final OS analysis of sacituzumab govitecan in TROPiCS-02 1:49
Final OS analysis of sacituzumab govitecan in TROPiCS-02
Sara Tolaney • 2 Jun 2023
ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBC 1:08
ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBC
Sara Tolaney • 2 Jun 2023
TROPiCS-02: sacituzumab govitecan in HR+/HER2- breast cancer 1:00
TROPiCS-02: sacituzumab govitecan in HR+/HER2- breast cancer
Sara Tolaney • 2 Jun 2023
Where are we in sequencing ADCs in HR+ breast cancer? 1:09
Where are we in sequencing ADCs in HR+ breast cancer?
Sara Tolaney • 2 Jun 2023
Important considerations in the management of HR+, HER2-negative early breast cancer 2:05
Important considerations in the management of HR+, HER2-negative early breast cancer
Sara Tolaney • 17 Mar 2023
Remaining questions regarding the use of frontline CDK4/6 inhibitors and endocrine therapy 2:07
Remaining questions regarding the use of frontline CDK4/6 inhibitors and endocrine therapy
Sara Tolaney • 17 Mar 2023
Why are we conducting clinical trials in countries that are unlikely to afford novel drugs? 3:08
Why are we conducting clinical trials in countries that are unlikely to afford novel drugs?
Sara Tolaney • 17 Mar 2023
ASCENT-04: sacituzumab govitecan and pembrolizumab in PD-L1-positive TNBC 1:58
ASCENT-04: sacituzumab govitecan and pembrolizumab in PD-L1-positive TNBC
Sara Tolaney • 13 Sep 2022
AMEERA-3: amcenestrant does not improve PFS in ER+/HER2- breast cancer 2:46
AMEERA-3: amcenestrant does not improve PFS in ER+/HER2- breast cancer
Sara Tolaney • 13 Sep 2022
What does the future hold for SERDs in ER+ breast cancer? 2:35
What does the future hold for SERDs in ER+ breast cancer?
Sara Tolaney • 13 Sep 2022
Breast cancer trials of interest at ESMO 2022 2:51
Breast cancer trials of interest at ESMO 2022
Sara Tolaney • 13 Sep 2022
Adjuvant treatment for stage I HER2+ breast cancer 4:16
Adjuvant treatment for stage I HER2+ breast cancer
Sara Tolaney • 12 May 2021
Dato-DXd: a new ADC on the block 1:25
Dato-DXd: a new ADC on the block
Sara Tolaney • 12 May 2021
CDK4/6 inhibitors in early stage HR+/HER2- disease 2:22
CDK4/6 inhibitors in early stage HR+/HER2- disease
Sara Tolaney • 12 May 2021
monarchE: patient-reported outcomes 1:59
monarchE: patient-reported outcomes
Sara Tolaney • 19 Mar 2021
monarchE: adjuvant abemaciclib in HR+ breast cancer 1:12
monarchE: adjuvant abemaciclib in HR+ breast cancer
Sara Tolaney • 18 Mar 2021
The content of VJOncology is intended for healthcare professionals